Compare Samsara Inc (IOT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Samsara Inc vs Organon & Co. Common Stock — how do they compare? Samsara Inc trades at $40.5 (market cap $24.17B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Samsara Inc is far larger — about 6.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Organon & Co. Common Stock for 0 Days on average.
| IOT | OGN | |
|---|---|---|
Market Cap | $24.17B | $3.62B |
Volume | 3,228,585 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $45.22 | $13.81 |
52-Week Low | $24.25 | $5.70 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $23.41B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.27, down 0.84% today, with a bullish technical signal from moving averages and a consensus analyst price target of $51.15. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.20 versus $0.16 expected, and revenue growth of 30% year-over-year. Recent news highlights partnerships and product launches, including the Samsara MCP for AI integration and a rewards program for drivers.
The outlook is positive due to robust revenue growth, expanding large-customer base, and analyst optimism, but risks include high valuation multiples (P/E of 275.13) and cash flow pressures. Investment opportunity lies in continued execution and market share gains, while investors should monitor margin sustainability and competitive dynamics.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
